5-methoxy-2-methyl-2,3-dihydro-1H-isoindol-1-one | 109803-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 5-methoxy-2-methyl-2,3-dihydro-1H-isoindol-1-one
• 英文别名: N-methyl-1,3-dihydro-5-methoxy-1-oxoisoindoline；5-methoxy-2-methylisoindolin-1-one；N-methyl-5-methoxyisoindolinone；5-methoxy-2-methyl-3H-isoindol-1-one
• CAS: 109803-60-3
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: ZPMTZEDIPYFSEM-UHFFFAOYSA-N

物化性质

• 熔点：
  105-107 °C
• 沸点：
  351.7±42.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methoxy-2-methyl-2,3-dihydro-1H-isoindol-1-one 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 ethyl 4-[(2-methyl-1-oxo-3H-isoindol-5-yl)oxy]butanoate
  参考文献：
  名称：

  [（N-烷基-1,3-二氧代-1H，3H-异吲哚-5-基）氧基]链烷酸，[（N-烷基-1-氧代-1H，3H-异吲哚-5-基]氧基的作用]丁酸和相关衍生物对原代星形胶质细胞培养物中氯的流入。

  摘要：

  业已表明，抑制氯离子流入并因此降低脑灰质星形细胞中主要细胞类型的细胞内氯水平的试剂在体外和体内均抑制星形胶质细胞的肿胀。在我们的实验室中，已经合成了4-[（（N-烷基-1,3-二氧杂-1H，3H-异吲哚基-5-基）氧基]链烷酸和相关衍生物，并测试了降低细胞内星形细胞氯化物水平的能力。建立了体外培养的大鼠星形胶质细胞模型。通常，具有氮取代基（例如相对小的烷基）的衍生物在0.1 mM和/或0.5 mM的水平上具有活性，而较大的取代基（例如环戊基和环己基）的活性较低。芳环上的卤素取代没有增强活性。

  DOI：

  10.1021/jm00393a020
• 作为产物：
  描述：

  1-(4-甲氧基-2-甲基苯基)乙酮 在 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 、 硫酸 、 溴 、 三乙胺 作用下， 以 四氯化碳 为溶剂， 反应 31.0h， 生成 5-methoxy-2-methyl-2,3-dihydro-1H-isoindol-1-one
  参考文献：
  名称：

  [（N-烷基-1,3-二氧代-1H，3H-异吲哚-5-基）氧基]链烷酸，[（N-烷基-1-氧代-1H，3H-异吲哚-5-基]氧基的作用]丁酸和相关衍生物对原代星形胶质细胞培养物中氯的流入。

  摘要：

  业已表明，抑制氯离子流入并因此降低脑灰质星形细胞中主要细胞类型的细胞内氯水平的试剂在体外和体内均抑制星形胶质细胞的肿胀。在我们的实验室中，已经合成了4-[（（N-烷基-1,3-二氧杂-1H，3H-异吲哚基-5-基）氧基]链烷酸和相关衍生物，并测试了降低细胞内星形细胞氯化物水平的能力。建立了体外培养的大鼠星形胶质细胞模型。通常，具有氮取代基（例如相对小的烷基）的衍生物在0.1 mM和/或0.5 mM的水平上具有活性，而较大的取代基（例如环戊基和环己基）的活性较低。芳环上的卤素取代没有增强活性。

  DOI：

  10.1021/jm00393a020

文献信息

• Tyrosine Kinase Inhibitor And Uses Thereof
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：US20170112833A1

  公开（公告）日：2017-04-27

  Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

  公开了一种公式(I)的化合物或其药物可接受的盐、酯或溶剂，或它们的立体异构体，可用作酪氨酸激酶抑制剂。还公开了制备该化合物的方法、包含该化合物的药物组合物和套件，以及该化合物的用途。该化合物可用作酪氨酸激酶抑制剂，或可用于减少或抑制细胞中EGFR或其突变体的活性，例如包含T790M突变的EGFR突变体，或用于治疗和/或预防与EGFR过度活动相关的疾病，如癌症。
• [EN] PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉ CHIMÈRE CIBLANT LA PROTÉOLYSE (PROTAC) AYANT UNE ACTIVITÉ DE LIAISON À L'UBIQUITINE LIGASE E3 ET CIBLANT UNE PROTÉINE ALPHA-SYNUCLÉINE POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2020041331A1

  公开（公告）日：2020-02-27

  The present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/ inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure. Such diseases or disorders are alpha-synucleinopathies or neurodegenerative diseases associated with alpha-synuclein accumulation and aggregation, such as e.g. Parkinson Disease, Alzheimer's Disease, dementia, dementia with Lewy bodies or multiple system atrophy, in particular Parkinson's Disease.

  本公开涉及双功能化合物，其作为α-突触核蛋白（目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，另一端为与目标蛋白结合的基团，使得目标蛋白靠近泛素连接酶以促使目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。这些疾病或紊乱是与α-突触核蛋白积累和聚集相关的α-突触核蛋白病或神经退行性疾病，例如帕金森病、阿尔茨海默病、痴呆症、带有Lewy小体的痴呆症或多系统萎缩，特别是帕金森病。
• TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas, Inc.

  公开号：US20180155322A1

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，这些化合物可用作雌激素受体（目标蛋白）的调节剂。特别是，本公开涉及包含在一段至少有一种Von Hippel-Lindau配体、一种cereblon配体、凋亡抑制蛋白配体、小鼠双分钟同源2配体或其组合的双功能化合物，这些配体与相应的E3泛素连接酶结合，在另一端有一个与目标蛋白结合的部分，使得目标蛋白被置于泛素连接酶附近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白降解/抑制相关的广泛药理活性。可以通过本公开的化合物和组合物治疗或预防由目标蛋白聚集或积累引起的疾病或障碍。
• Synthesis of phosphorylated isoindolinone derivatives
  作者：Andrzej Jóźwiak、Piotr M. Zagórski、Mieczysław W. Płotka、Dariusz Cal

  DOI：10.1016/j.tetlet.2014.02.127

  日期：2014.4

  The synthesis of diethyl [2-(2-alkyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)ethyl]phosphonates and diethyl [3-(2-alkyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)propyl]phosphonates, via metallation (sec-BuLi) of N-substituted isoindolin-1-ones and then the reaction of the generated lithiated species 4 with diethyl vinylphosphonate or diethyl 3-bromopropylphosphonate, respectively, is described.

  [2-（2-烷基-3-氧代-2,3-二氢-1 H-异吲哚-1-基）乙基]膦酸酯和二乙基[3-（2-烷基-3-氧代-2， 3-二氢-1H-异吲哚-1-基）丙基]膦酸酯，通过N-取代的异吲哚啉-1-酮的金属化（sec -BuLi），然后使生成的锂化物质4与乙烯基膦酸二乙酯或3-乙基二乙基酯反应分别描述了溴丙基膦酸酯。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE
  申请人：Arvinas, Inc.

  公开号：US20180177750A1

  公开（公告）日：2018-06-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为增强子锁定同源2的调节剂而发挥作用。具体而言，本公开涉及包含一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，另一端含有结合目标蛋白的基团，使目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。